Recapitalization vs. Strategic Sale: Determining your path and approach to growing your business
Presented By: Waller and Cherry Bekaert LLP
As your company matures, its financial needs change. Hear from a panel of c-suite executives and M&A advisors as they discuss the pros and cons of recapitalizing your business vs. a strategic sale and break down how to identify, assemble, and deploy that capital to fuel growth.
Moderator:
Partner
Waller
Companies and investors in healthcare, technology, manufacturing, distribution and other industries rely on Tyson Bickley for counsel in a wide range of strategic corporate transactions and business arrangements. He assists venture capital and private equity funds in investments in new and emerging companies, and he advises startups and early-stage companies in securities offerings to access the capital needed for growth. Tyson’s transactional experience also includes the representation of well-established and publicly traded companies in complex mergers, acquisitions, joint ventures, and dispositions.
Tyson rejoined Waller in 2017 after serving as Chief Development Officer at Contessa Health where he led successful development efforts for joint ventures with health systems and health plans to participate in bundled payment programs for home hospitalization and other patient-centered care models.
Panelists:
CEO
Psychiatric Medical Care
J.R. Greene, FACHE, is the Chief Executive Officer of Psychiatric Medical Care (PMC), a behavioral healthcare management company headquartered in Nashville, TN. In June 2009, J.R. became CEO and transformed the company into one of the key innovators within the behavioral health inpatient and outpatient markets with operations across the United States.
Partner and National Leader of Healthcare Transaction Advisory Services
Cherry Bekaert LLP
Steve has worked on more than 100 middle-market healthcare transactions advising on financial due diligence; mergers and acquisitions; strategic financial planning; and quality of earnings engagements.
Steve’s industry expertise includes deals for private equity groups, venture capital funds, investment bankers, healthcare REITs, and a diverse group of healthcare providers ranging from $1 million to $400 million in transaction value.